The Latest Breaking News from Clearside Biomedical

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Clearside Biomedical Inc (NASDAQ: CLSD) shares are trading higher Friday after the company reported better-than-expected fourth-quarter financial results. 

Benzinga's “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's Movers tool. Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks.